Alternating triple therapy (ATT) regimen
| Drugs . | Dose (mg/m2) . | Days . | Route . | Treatment interval (d) . |
|---|---|---|---|---|
| CHOD-Bleo15 | 21 | |||
| Cyclophosphamide | 750 | 1 | IV | |
| Doxorubicin | 50 (total) | 1-2 | IV, CI | |
| Vincristine | 1.4 (total) | 1-2 | IV, CI | |
| Bleomycin* | 4 | 1 | IV | |
| Bleomycin* | 10 (total) | 1-2 | IV, CI | |
| Dexamethasone | 40 (daily)‡ | 1-4 | PO | |
| ESHAP | 21 | |||
| Etoposide | 40 (daily) | 1-4 | I.V | |
| Methylprednisolone | 500 (daily)‡ | 1-5 | IV | |
| Cytarabine† | 2000 | 5 | IV | |
| Cisplatin | 100 (total) | 1-4 | IV, CI | |
| NOPP | 28 | |||
| Mitoxantrone | 10 | 1 | IV | |
| Vincristine | 1.4 | 1 | IV | |
| Procarbazine | 100 (daily) | 1-14 | PO | |
| Prednisone | 100 (daily)‡ | 1-5 | PO |
| Drugs . | Dose (mg/m2) . | Days . | Route . | Treatment interval (d) . |
|---|---|---|---|---|
| CHOD-Bleo15 | 21 | |||
| Cyclophosphamide | 750 | 1 | IV | |
| Doxorubicin | 50 (total) | 1-2 | IV, CI | |
| Vincristine | 1.4 (total) | 1-2 | IV, CI | |
| Bleomycin* | 4 | 1 | IV | |
| Bleomycin* | 10 (total) | 1-2 | IV, CI | |
| Dexamethasone | 40 (daily)‡ | 1-4 | PO | |
| ESHAP | 21 | |||
| Etoposide | 40 (daily) | 1-4 | I.V | |
| Methylprednisolone | 500 (daily)‡ | 1-5 | IV | |
| Cytarabine† | 2000 | 5 | IV | |
| Cisplatin | 100 (total) | 1-4 | IV, CI | |
| NOPP | 28 | |||
| Mitoxantrone | 10 | 1 | IV | |
| Vincristine | 1.4 | 1 | IV | |
| Procarbazine | 100 (daily) | 1-14 | PO | |
| Prednisone | 100 (daily)‡ | 1-5 | PO |
IV, intravenously; CI, continuous infusion; PO, oral.
Bleomycin 4 mg/m2 on day 1, followed by 10 mg IV, CI over 48 hours on days 1 and 2.
Cytarabine 2 g/m2 by 2-hour infusion on day 5 after platinum.
Steroid doses were given at the stated fixed dose, not mg/m2.
ATT chemotherapy continued for a total of 12 cycles, 4 of each regimen.